top of page

Mwandishi:

Mhariri:

Dkt. Sospeter M, MD

Dkt. Charles W, MD

9 Juni 2020 09:48:10

Vipimo vya kisukari

Vipimo vya kisukari

Je vipimo gani hufanywa ukiwa hospitali?

Kipimo cha sukari kabla hujala kitu chochote asubuhi toka ulipokula usiku wa kuamkia siku hiyo (fasting blood glucose-FBG)


Kipimo hiki husomwa kwa vizio vya aina mbili ( mg/dl au mmol/L ), utasemekana sukali yako ipo juu endapo kipimo kikizidi miligramu 126 kwa kila desilita 1 ya damu (yaani 126mg/dl) au milimole 7 kwa kila lita moja ya damu (yaani 7mmol/L)



  • Sukari kuwa 200mg/dl(11.1mmol/L) au zaidi baada ya masaa mawili ya kupewa sukari yenye gramu 75- kipimo hiki huitwa oral glucose torelance test (OGTT)

  • Sukari kuwa zaidi ya 200mg/dl(11.1mmol/L) au zaidi unapopimwa ukiwa ushakula au kwa jina jingine “Rondum blood glucose”-RBG

  • Kipimo kingine ni cha kiwango cha sukari kwenye chembe za damu za hemoglobin A1c (HBA1c) ambapo ikiwa asilimia 6.5 au zaidi mtu anaitwa anakisukari

Mtu mwenye sifa zifuatazo anatakiwa kuwa anapima kisukari hata kama hana kisukari

  • Shinikizo la damu kuwa juu zaidi ya 135/80mmHg

  • Uzito kupita kiasi au ana vihatarishi kama vya kupata kisukari kama(kuwa na ndugu wa baba/mama mmoja mwenye kisukari, shinikizo la damu zaidi ya 140/90 na kiwango cha lehamu nzuri kwenye damu chini ya 35mg/dl au kiwango cha triglceride kwenye damu zaidi ya 250mg/dl)

  • Kuwa na miaka zaidi ya 45 hata kama hauna sifa za hapo juu

Imeboreshwa

11 Desemba 2021 14:18:30

Uly clinic inakushauri siku zote uwasiliane na daktari wako kabla ya kuchukua hatua yoyote dhidi ya afya yako.

Wasiliana na daktari wa ULY clinic kwa kubonyeza 'Pata Tiba' au kwa kupiga namba za simu chini ya tovuti hii.

Rejea za mada hii;

​

  1. Tessier D, Meneilly GS. Diabetes management in the elderly. In: Gerstein HC, ed. Evidence-based diabetes care. Hamilton: BC Decker Inc., 2001, pg. 370–9.

  2. Lipska KJ, De Rekeneire N, Van Ness PH, et al. Identifying dysglycemic states in older adults: Implications of the emerging use of hemoglobin A1c. J Clin Endocrinol Metab 2010;95:5289–95.

  3. Crandall J, Schade D, Ma Y, et al. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006;61:1075–81.

  4. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072–7.

  5. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096– 105.

  6. Inzucchi SE, Viscoli CM, Young LH, et al. Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease. Diabetes Care 2016;39:1684–92.

  7. Kronsbein P, Jorgens V, Muhlhauser I, et al. Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes. Lancet 1988;2:1407–11.

  8. Wilson W, Pratt C. The impact of diabetes education and peer support upon weight and glycemic control of elderly persons with NonInsulin Dependent Diabetes Mellitus (NIDDM). Am J Public Health 1987;77:634–5.

  9. Braun AK, Kubiak T, Kuntsche J, et al. SGS: A structured treatment and teaching programme for older patients with diabetes mellitus–a prospective randomised controlled multi-centre trial. Age Ageing 2009;38:390–6.

  10.  Fagan PJ, Schuster AB, Boyd C, et al. Chronic care improvement in primary care: Evaluation of an integrated pay-for-performance and practice-based care coordination program among elderly patients with diabetes. Health Serv Res 2010;45:1763–82.

  11. McGovern MP, Williams DJ, Hannaford PC, et al. Introduction of a new incentive and target-based contract for family physicians in the UK: Good for older patients with diabetes but less good for women? Diabet Med 2008;25:1083–9.

  12. Maar MA, Manitowabi D, Gzik D, et al. Serious complications for patients, care providers and policy makers: Tackling the structural violence of First Nations people living with diabetes in Canada. Int Indigenous Policy J 2011;21:http://ir.lib.uwo.ca/iipj/vol2/iss1/6. Article 6.Imechukuliwa 05.06.2020

  13.  Jacklin KM, Henderson RI, Green ME, et al. Health care experiences of Indigenous people living with type 2 diabetes in Canada. CMAJ 2017;189:E106– 12.

  14. Chandler MJ, Lalonde C. Cultural continuity as a protective factor against suicide in First Nations Youth. Horizons 2008;10:68–72.

  15. Oster RT, Grier A, Lightning R, Mayan MJ, Toth EL. Cultural continuity, traditional Indigenous language, and diabetes in Alberta First Nations: A mixed methods study. Int J Equity Health 2014;13:92. doi:10.1186/s12939-014- 0092-4.

  16. Truth and Reconciliation Commission of Canada. Truth and reconcilliation commission of Canada: calls to action. Winnipeg, MB: Truth and Reconciliation Commission of Canada 2012. 2015. http://www.trc.ca/websites/ trcinstitution/File/2015/Findings/Calls_to_Action_English2.pdf.Imechukuliwa 05.06.2020

  17.  Yu CH, Zinman B. Type 2 diabetes and impaired glucose tolerance in aboriginal populations: A global perspective. Diabetes Res Clin Pract 2007;78:159– 70.

  18. Gracey M, King M. Indigenous health part 1: Determinants and disease patterns. Lancet 2009;374:65–75.

  19. Chronic Disease Surveillance and Monitoring Division, Centre for Chronic Disease Prevention and Control. Diabetes in Canada: Facts and figures from a public health perspective. Ottawa, ON: Public Health Agency of Canada, 2011 http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts -figures-faits-chiffres-2011/index-eng.php. Imechukuliwa 05.06.2020

  20. Turin TC, Saad N, Jun M, et al. Lifetime risk of diabetes among first nations and non-first nations people. CMAJ 2016;188:1147–53.

  21. Singer J, Putulik Kidlapik C, Martin B, et al. Food consumption, obesity and abnormal glycaemic control in a Canadian Inuit community. Clin Obes 2014;4:316– 23.

​

bottom of page